<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38116037</article-id><article-id pub-id-type="pmc">PMC10728868</article-id><article-id pub-id-type="doi">10.3389/fmed.2023.1338939</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Editorial</subject></subj-group></subj-group></article-categories><title-group><article-title>Editorial: Next generation <italic>in vitro</italic> models to study chronic pulmonary diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thiam</surname><given-names>Fama</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/2146259/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Faiz</surname><given-names>Alen</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/1263513/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Pouwels</surname><given-names>Simon D.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/1564119/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Osei</surname><given-names>Emmanuel T.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="http://loop.frontiersin.org/people/1522555/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Biology, University of British Columbia</institution>, <addr-line>Kelowna, BC</addr-line>, <country>Canada</country></aff><aff id="aff2"><sup>2</sup><institution>Faculty of Science, Respiratory Bioinformatics and Molecular Biology, University of Technology Sydney</institution>, <addr-line>Sydney, NSW</addr-line>, <country>Australia</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Pulmonology, University Medical Center Groningen, University of Groningen</institution>, <addr-line>Groningen</addr-line>, <country>Netherlands</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen</institution>, <addr-line>Groningen</addr-line>, <country>Netherlands</country></aff><aff id="aff5"><sup>5</sup><institution>University Medical Center Groningen, Groningen Research Institute for Asthma and Chronic Obstructive Pulmonary Disease, University of Groningen</institution>, <addr-line>Groningen</addr-line>, <country>Netherlands</country></aff><aff id="aff6"><sup>6</sup><institution>Centre for Heart Lung Innovation, St. Paul's Hospital</institution>, <addr-line>Vancouver, BC</addr-line>, <country>Canada</country></aff><author-notes><fn fn-type="edited-by"><p>Edited and reviewed by: Dawei Yang, Fudan University, China</p></fn><corresp id="c001">*Correspondence: Emmanuel T. Osei <email>emmanuel.osei@ubc.ca</email></corresp><fn fn-type="equal" id="fn001"><p>&#x02020;These authors have contributed equally to this work and share last authorship</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>10</volume><elocation-id>1338939</elocation-id><history><date date-type="received"><day>15</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Thiam, Faiz, Pouwels and Osei.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Thiam, Faiz, Pouwels and Osei</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="RA1" xlink:href="https://www.frontiersin.org/research-topics/29554/next-generation-in-vitro-models-to-study-chronic-pulmonary-diseases" ext-link-type="uri">Editorial on the Research Topic <article-title>Next generation <italic>in vitro</italic> models to study chronic pulmonary diseases</article-title></related-article><kwd-group><kwd><italic>in vitro</italic> models</kwd><kwd>chronic pulmonary disease</kwd><kwd>air liquid interface (ALI)</kwd><kwd>precision cut lung slice</kwd><kwd>CAD modeling</kwd><kwd><italic>ex vivo</italic> models</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="11"/><page-count count="3"/><word-count count="1836"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pulmonary Medicine</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Chronic pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), tuberculosis (TB), and idiopathic pulmonary fibrosis (IPF), impact millions of people and are leading causes of death worldwide (<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>). Hence, a vast amount of research effort has been made to find early detection and curative therapies for these diseases. Researchers utilize several novel <italic>in vitro</italic> and <italic>ex vivo</italic> models to investigate the underlying mechanisms behind respiratory diseases. This is intended to help create targeted treatments that can aid in assessing and understanding novel disease mechanisms to subsequently improve the prognosis and quality of life of patients living with chronic pulmonary illnesses.</p><p>The use of bioinformatics and surgical models to improve diagnostics in respiratory diseases has the potential to impact clinical outcomes. In this Research Topic, studies from <ext-link xlink:href="https://doi.org/10.3389/fmed.2022.830515" ext-link-type="uri">Oloko-Oba and Viriri</ext-link> and <ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1172622" ext-link-type="uri">Gupta et al.</ext-link> assessed computer-aided diagnostic (CAD) systems related to TB diagnosis from the common and sensitive chest X-ray (CXR), which use deep learning techniques as well as a cellulose matrix absorptive probe for bronchial epithelial lining fluid (bELF) in the airways, respectively. From the systematic review of <ext-link xlink:href="https://doi.org/10.3389/fmed.2022.830515" ext-link-type="uri">Oloko-Oba and Viriri</ext-link>, it was found that although most studies were developmental instead of being used in the clinic, the use of public and training datasets presented great potential for the use of CAD systems to improve TB diagnosis. In line with lung disease clinical diagnostics, <ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1172622" ext-link-type="uri">Gupta et al.</ext-link> also discovered that the newly established bELF probes maintained their integrity with no residual fibers <italic>in vivo</italic> and obtained samples rich in proteins and with higher levels of inflammatory cytokines compared to the samples obtained from bronchial wash fluid. Ultimately, this high-precision probe is a novel technique for analyzing biomarkers in a consistent and accurate manner that will aid in early detection of lung disease (<ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1172622" ext-link-type="uri">Gupta et al.</ext-link>).</p><p>In addition to diagnostics, air liquid interface (ALI) cultured cells have been used to assess different factors in disease severity, which is necessary to advance therapeutic treatments. In this Research Topic, <ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1144050" ext-link-type="uri">Ito et al.</ext-link> used ALIs to show that age was a significant factor affecting respiratory syncytial virus (RSV) infection, with increased viral load and viral genome copies, lower viral clearance, higher inflammation, increased cell damage, mucin production, and cellular senescence in ALIs of older people (&#x0003e;65 years) compared to younger individuals (&#x02264; 60 years). Additionally, <ext-link xlink:href="https://doi.org/10.3389/fmed.2022.897695" ext-link-type="uri">Kasper et al.</ext-link> compared an ALI model to a submerged culture model to show that SARS-CoV-2 entry genes, such as angiotensin converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2), cathepsin L (CTSL), and tyrosine protein kinase receptor UFO (AXL) in human primary small airway epithelial cells (SAEC) or bronchial epithelial cells (HBEC), are affected more by culture conditions than individual donor conditions.</p><p>Lung organoids are another <italic>in vitro</italic> model that is used to assess cell mechanisms and their implications in pulmonary diseases [<ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1182368" ext-link-type="uri">Wisman et al.</ext-link>; (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>)]. Here, <ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1182368" ext-link-type="uri">Wisman et al.</ext-link> developed organoids of MRC-5 and unfractionated lung cell suspensions or isolated EpCAM<sup>+</sup> distal lung tissue pulmonary epithelial cells from individuals with/without IPF. Organoids from IPF-derived cells were larger compared to isolated EpCAM<sup>+</sup> cell-organoids, suggesting intrinsic progenitor dysfunction. Unfractionated cell suspensions from IPF-derived lungs also resulted in a higher number of organoids, suggesting a dysregulated communication between epithelial and stroma cells in IPF, which may lead to distal lung alveolar impairment (<ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1182368" ext-link-type="uri">Wisman et al.</ext-link>).</p><p>Another important model is the precision cut lung slice (PCLS) model, where thin slices of lung tissue are cultured <italic>in vitro</italic> for studies into disease mechanisms (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). In this Research Topic, <ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1177665" ext-link-type="uri">Cervantes et al.</ext-link> established PCLS from donors without a history of disease and exposed them to particulate matter from Afghanistan (PMa) (<xref rid="B8" ref-type="bibr">8</xref>) or particulate matter from California as a control (PMc) to investigate the mechanisms related to unique military deployment airway symptoms. Interestingly, PCLS was used to show that PMa increased airway hyperresponsiveness (AHR), but PMc had no effect (<ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1177665" ext-link-type="uri">Cervantes et al.</ext-link>). Additionally, PMa co-stimulated with IL-13 resulted in significantly amplified AHR compared to PMc co-stimulations (<ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1177665" ext-link-type="uri">Cervantes et al.</ext-link>).</p><p>Another important mechanism underlying respiratory disease pathogenesis is the disruption of the epithelial barrier integrity (<xref rid="B9" ref-type="bibr">9</xref>). <ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1214130" ext-link-type="uri">Hsieh et al.</ext-link> used the Electric Cell-substrate Impedance Sensing (ECIS) system to assess the effect of different ECM substrates on the barrier integrity and attachment of basal airway epithelial cells. It was shown that airway epithelial cells attached faster on fibronectin, collagen I, and collagen III than on collagen IV and laminin. Further, fibronectin and collagen I enabled the fastest epithelial barrier formation compared to the other ECM proteins. This study demonstrated a potential protective role of these ECM proteins in pathological lung conditions (<ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1214130" ext-link-type="uri">Hsieh et al.</ext-link>).</p><p>Respiratory cancers are a prominent source of cancer incidence and mortality worldwide, therefore investigations into their mechanisms of drug resistance are essential to identify novel treatment targets (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). <ext-link xlink:href="https://doi.org/10.3389/fonc.2023.1145333" ext-link-type="uri">Tuffour et al.</ext-link> used CRISPER-Cas-9 gene editing to knockout the <italic>CASD1</italic> and <italic>SIAE</italic> genes, which are an important part of the breast cancer resistance protein (BCRP), a main ATP-binding cassette (ABC) transporter protein involved in multidrug resistant (MDR) pathways. Here, using CRISPR-gene editing and drug sensitivity analysis, it was shown that deacetylated Sias are utilized by cancer cells to overexpress BCRP as a pathway of MDR, which can be used to further advance the effectiveness of chemotherapies.</p><p><italic>Ex vivo</italic> models have also been utilized to study the biological methods of disease and potentially identify mechanisms for therapeutics due to their ability to mimic the <italic>in vivo</italic> physiology. <ext-link xlink:href="https://doi.org/10.3389/fmed.2023.1144754" ext-link-type="uri">Ievlev et al.</ext-link> created a ferret tracheal model for injury and cell engraftment using tracheal explants and found a semblance to surface airway epithelium (SAE) and submucosal glands (SMGs). Consistent results in line with published data on <italic>in vivo</italic> injury systems were found after injury experiments. A 3D-printed culture chamber that allows imaging of ferret tissue explants was set up, which aided ferret cell ALI establishment.</p><p>In this Research Topic, various studies utilized a breadth of tools including CAD modeling, pulmonary sampling devices, ALIs, PCLS, ECIS, CRISPR, and <italic>ex vivo</italic> systems to study different mechanisms of pulmonary diseases as well as diagnostics and to perform drug studies. These prove the utility and adaptability of these systems for future studies and the advancement of the pulmonary field.</p><sec sec-type="author-contributions" id="s1"><title>Author contributions</title><p>FT: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. AF: Conceptualization, Writing &#x02013; review &#x00026; editing. SP: Conceptualization, Writing &#x02013; review &#x00026; editing. EO: Conceptualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec></body><back><sec sec-type="COI-statement" id="conf1"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s3"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>L&#x000f3;pez-Campos</surname><given-names>JL</given-names></name><name><surname>Ancochea</surname><given-names>J</given-names></name><name><surname>Coebergh</surname><given-names>JW</given-names></name><name><surname>Soriano</surname><given-names>JB</given-names></name></person-group>. <article-title>International trends in COPD mortality, 1995-2017</article-title>. <source>Eur Respir J</source>. (<year>2019</year>) <fpage>54</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01791-2019</pub-id><pub-id pub-id-type="pmid">31744832</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>TM</given-names></name><name><surname>Bendstrup</surname><given-names>E</given-names></name><name><surname>Dron</surname><given-names>L</given-names></name><name><surname>Langley</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Khalid</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Global incidence and prevalence of idiopathic pulmonary fibrosis</article-title>. <source>Respir Res</source>. (<year>2021</year>) <volume>22</volume>:<fpage>197</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-021-01791-z</pub-id><pub-id pub-id-type="pmid">34233665</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacNeil</surname><given-names>A</given-names></name><name><surname>Glaziou</surname><given-names>P</given-names></name><name><surname>Sismanidis</surname><given-names>C</given-names></name><name><surname>Date</surname><given-names>A</given-names></name><name><surname>Maloney</surname><given-names>S</given-names></name><name><surname>Floyd</surname></name><name><surname>K</surname></name></person-group>. <article-title>Global epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2018</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. (<year>2020</year>) <volume>69</volume>:<fpage>281</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6911a2</pub-id><pub-id pub-id-type="pmid">32191687</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkauskas</surname><given-names>CE</given-names></name><name><surname>Chung</surname><given-names>MI</given-names></name><name><surname>Fioret</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Katsura</surname><given-names>H</given-names></name><name><surname>Hogan</surname><given-names>BL</given-names></name></person-group>. <article-title>Lung organoids: current uses and future promise</article-title>. <source>Development</source>. (<year>2017</year>) <volume>144</volume>:<fpage>986</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1242/dev.140103</pub-id><pub-id pub-id-type="pmid">28292845</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matkovic Leko</surname><given-names>I</given-names></name><name><surname>Schneider</surname><given-names>RT</given-names></name><name><surname>Thimraj</surname><given-names>TA</given-names></name><name><surname>Schrode</surname><given-names>N</given-names></name><name><surname>Beitler</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>HY</given-names></name><etal/></person-group>. <article-title>A distal lung organoid model to study interstitial lung disease, viral infection and human lung development</article-title>. <source>Nat Protoc</source>. (<year>2023</year>) <volume>18</volume>:<fpage>2283</fpage>&#x02013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1038/s41596-023-00827-6</pub-id><pub-id pub-id-type="pmid">37165073</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsafadi</surname><given-names>HN</given-names></name><name><surname>Uhl</surname><given-names>FE</given-names></name><name><surname>Pineda</surname><given-names>RH</given-names></name><name><surname>Bailey</surname><given-names>KE</given-names></name><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>DE</given-names></name><etal/></person-group>. <article-title>Applications and approaches for three-dimensional precision-cut lung slices. disease modeling and drug discovery</article-title>. <source>Am J Respir Cell Mol Biol</source>. (<year>2020</year>) <volume>62</volume>:<fpage>681</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2019-0276TR</pub-id><pub-id pub-id-type="pmid">31991090</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Betts</surname><given-names>C</given-names></name><name><surname>Cunoosamy</surname><given-names>DM</given-names></name><name><surname>&#x000c5;berg</surname><given-names>PM</given-names></name><name><surname>Hornberg</surname><given-names>JJ</given-names></name><name><surname>Sivars</surname><given-names>KB</given-names></name><etal/></person-group>. <article-title>Use of precision cut lung slices as a translational model for the study of lung biology</article-title>. <source>Respir Res</source>. (<year>2019</year>) <volume>20</volume>:<fpage>162</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-019-1131-x</pub-id><pub-id pub-id-type="pmid">31324219</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>R</given-names></name><name><surname>Rose</surname><given-names>CS</given-names></name><name><surname>Downey</surname><given-names>GP</given-names></name><name><surname>Day</surname><given-names>BJ</given-names></name><name><surname>Chu</surname><given-names>HW</given-names></name></person-group>. <article-title>Role of particulate matter from Afghanistan and Iraq in deployment-related lung disease</article-title>. <source>Chem Res Toxicol</source>. (<year>2021</year>) <volume>34</volume>:<fpage>2408</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.1c00090</pub-id><pub-id pub-id-type="pmid">34808040</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlier</surname><given-names>FM</given-names></name><name><surname>de Fays</surname><given-names>C</given-names></name><name><surname>Pilette</surname><given-names>C</given-names></name></person-group>. <article-title>Epithelial barrier dysfunction in chronic respiratory diseases</article-title>. <source>Front Physiol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>691227</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2021.691227</pub-id><pub-id pub-id-type="pmid">34248677</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanker</surname><given-names>M</given-names></name><name><surname>Willcutts</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Ramesh</surname><given-names>R</given-names></name></person-group>. <article-title>Drug resistance in lung cancer</article-title>. <source>Lung Cancer</source>. (<year>2010</year>) <volume>1</volume>:<fpage>23</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.2147/LCTT.S6861</pub-id><pub-id pub-id-type="pmid">28210104</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thandra</surname><given-names>KC</given-names></name><name><surname>Barsouk</surname><given-names>A</given-names></name><name><surname>Saginala</surname><given-names>K</given-names></name><name><surname>Aluru</surname><given-names>JS</given-names></name></person-group>. <article-title>Epidemiology of lung cancer</article-title>. <source>Contemp Oncol</source>. (<year>2021</year>) <volume>25</volume>:<fpage>45</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.5114/wo.2021.103829</pub-id></mixed-citation></ref></ref-list></back></article>
